MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Attackers strike at businesses with identity theft as their top goal.

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

The age of hybrid work is here. 76% of companies say they have shifted to a hybrid work strategy, splitting work hours between an office and remote environment. Only 11% of teams say they’re planning ...

From having the ability to remove agents and detect malicious scripting to probing the behavior of machines rather than signature models, here are eight things companies need in an endpoint security ...

AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet ...

With ASP.NET Core 7, we can take advantage of the newly introduced IEndpointFilter interface to create filters and attach them to the endpoints in our minimal APIs. These filters can be used to modify ...

The rapid pace of digital transformation has increased operational efficiency and enhanced the customer experience – but it has also created a nightmare for CISOs. From mobile devices scattered across ...

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week ...